Minimization of drug–drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators
Keywords: Aβ, amyloid beta; AD, Alzheimer’s disease; DDIs, drug–drug interactions; GSM, gamma-secretase modulator; iv, intravenous; mg/kg, milligrams per kilogram of body weight; PD, pharmacodynamic; PK, pharmacokinetic; po, per os (by mouth); SAR, structure–activi